Publications by authors named "C Gomez-Manzano"
Glioblastoma (GBM) is the most prevalent malignant brain tumor. Current standard-of-care treatments offer limited benefits for patient survival. Virotherapy is emerging as a novel strategy to use oncolytic viruses (OVs) for the treatment of GBM.
View Article and Find Full Text PDFArticle Synopsis
- There are major gaps in understanding how immunotherapy affects the nervous system in children, mostly due to a lack of research focused on pediatric patients.
- Identifying and grading the neurotoxic effects of immunotherapy in children is complicated by inconsistent terminology and the variation in treatment responses based on factors like disease type and therapy methods.
- The review emphasizes the need for further research into the specific neurotoxic effects of various immunotherapy approaches in pediatric oncology, as well as the unique challenges presented by combining therapies.
Pediatric brain tumors are the most common solid tumors in children. Even to date, with the advances in multimodality therapeutic management, survival outcomes remain dismal in some types of tumors, such as pediatric-type diffuse high-grade gliomas or central nervous system embryonal tumors. Failure to understand the complex molecular heterogeneity and the elusive tumor and microenvironment interplay continues to undermine therapeutic efficacy.
View Article and Find Full Text PDFArticle Synopsis
- The text refers to a correction made to a published article identified by its DOI (Digital Object Identifier) 10.1016/j.omton.2024.200787.* -
- This implies that there were errors or inaccuracies in the original article that needed to be addressed.* -
- The correction ensures that readers have access to the right information for accuracy in research or study.*
Article Synopsis
- Glioblastoma has a low 5-year survival rate of 6.8%, prompting research into new treatments like the engineered adenovirus Delta-24-RGDOX, which interacts with immune systems.* -
- This study explores the link between gut microbiota and the effectiveness of oncolytic viroimmunotherapy, discovering that changes in gut bacteria were associated with better survival rates in treated mice.* -
- Results indicate that depleting CD4 T cells led to altered gut microbiota, reduced survival, and decreased effectiveness of the therapy, highlighting the importance of gut health in cancer treatment outcomes.*